
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings is projected to achieve 2025 sales of $7.85 billion and adjusted EPS of $8.23, reflecting growth rates of 4.0% and 2.9%, respectively. The company is anticipated to benefit from operational margin expansion of approximately 30 basis points, aided by its recent spin-out of non-core businesses, which is expected to contribute significantly over time. Positive momentum is noted in the knees and hips segments due to successful new product launches and increased penetration of advanced technologies, indicating a strong position in higher-growth end-markets.
Bears say
The analysis of Zimmer Biomet Holdings indicates a negative outlook primarily due to anticipated revenue growth slowing to 2% or less, driven by weak demand for ROSA robots and disappointing launches of new products. Additionally, projected margin contraction and earnings guidance falling below consensus—$8.25 at the midpoint compared to a consensus of $8.56—further exacerbate concerns regarding financial performance. The firm also faces significant risks, including slower orthopedic market growth, adverse pricing trends, and potential challenges from acquisitions that could dilute earnings.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares